CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 171 enrolled
Drug / intervention
Tadalafil +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02431754
NCT02431754Phase 4Completed
CompareCT.gov

A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment)

Eli Lilly and Company·interventional·Posted May 1, 2015·Updated Jul 2, 2017

In Brief

A Phase 4 clinical trial evaluating Tadalafil, Placebo, and 1 other intervention for Benign Prostatic Hyperplasia. Completed, enrolled 171 participants across 9 sites.

Detailed Summary

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as tadalafil in participants with benign prostatic hyperplasia who are being treated with an alpha1 blocker. This study has two treatment periods. Participants will receive tadalafil or placebo in each treatment period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia
CountriesJapan
CollaboratorsNippon Shinyaku Co., Ltd.

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 1, 2015
Enrollment StartApr 1, 2015
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.2 years ago

Interventions

Tadalafildrug

Administered orally

Placebodrug

Administered orally

Alpha1 Blockerdrug

Administered orally